title: A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
authors.affiliation: Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Wassmann
authors.forename: N
authors.initials: N
authors.lastname: Gökbuget
authors.forename: U J
authors.initials: UJ
authors.lastname: Scheuring
authors.forename: A
authors.initials: A
authors.lastname: Binckebanck
authors.forename: R
authors.initials: R
authors.lastname: Reutzel
authors.forename: H
authors.initials: H
authors.lastname: Gschaidmeier
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: O G
authors.initials: OG
authors.lastname: Ottmann
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate